PROGRAM-2
hematological malignancies, autoimmune disorders
Pre-ClinicalActive
Key Facts
Indication
hematological malignancies, autoimmune disorders
Phase
Pre-Clinical
Status
Active
Company
About Optieum Biotechnologies
A Japanese biotech developing optimized CAR-T therapies for solid tumors and autoimmune disorders using its proprietary Eumbody discovery platform.
View full company profile